Dr. Ashley Cauthen, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Florida State University College of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 2,544
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Florida State University College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
FL license ME112254
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Midstate Skin Institute LLC (18 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 2,544
- Services billed
- 21,399
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 7,595 | 1,261 |
| Injection, tildrakizumab, 1 mg | 3,400 | 11 |
| Established patient office or other outpatient visit, 20-29 minutes | 3,275 | 2,294 |
| Destruction of precancer skin growth, 1 growth | 2,113 | 1,597 |
| Biopsy of related skin growth, first growth | 1,372 | 1,097 |
| Destruction of skin growth, 1-14 growths | 1,138 | 954 |
| Established patient office or other outpatient visit, 30-39 minutes | 794 | 665 |
| Biopsy of related skin growth, each additional growth | 610 | 376 |
| Application of ultraviolet light to skin | 596 | 26 |
| New patient office or other outpatient visit, 30-44 minutes | 308 | 308 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 184 payments worth $90,991 in total to this clinician.
| Galderma Laboratories, L.P. | $53,160 |
|---|---|
| Amgen Inc. | $35,142 |
| UCB, Inc. | $522 |
| Regeneron Healthcare Solutions, Inc. | $379 |
| AbbVie Inc. | $342 |
| Sun Pharmaceutical Industries Inc. | $338 |
| Botanix Sb Inc | $240 |
| Janssen Biotech, Inc. | $222 |
| Compensation for services other than consulting (speaking, faculty) | $79,025 |
|---|---|
| Travel and Lodging | $7,693 |
| Food and Beverage | $4,168 |
| Education | $105 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Galderma Laboratories, L.P. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Amgen Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
All 39 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Galderma Laboratories, L.P. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Galderma Laboratories, L.P. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Amgen Inc. Oct 23, 2025 | Travel and Lodging OTEZLA · Inflammation · travel to Saint Petersburg, FL · in-kind | $852 |
| Amgen Inc. Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $650 |
| Regeneron Healthcare Solutions, Inc. Oct 7, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $5.00 |
| Amgen Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $650 |
| Amgen Inc. Sep 5, 2025 | Travel and Lodging OTEZLA · Inflammation · travel to Sarasota, FL · in-kind | $1,086 |
| Galderma Laboratories, L.P. Aug 21, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to LEESBURG, FL · in-kind | $39.20 |
| Galderma Laboratories, L.P. Aug 21, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to THE VILLAGES, FL · in-kind | $24.92 |
| Galderma Laboratories, L.P. Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Galderma Laboratories, L.P. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Aug 8, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Galderma Laboratories, L.P. Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $600 |
| Janssen Biotech, Inc. Jul 1, 2025 | Education TREMFYA · Immunology · in-kind | $99.99 |
| Amgen Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $650 |
| Amgen Inc. Jun 27, 2025 | Travel and Lodging OTEZLA · Inflammation · travel to Tampa, FL · in-kind | $1,131 |
| Galderma Laboratories, L.P. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. May 29, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to CLEARWATER, FL · in-kind | $2,069 |
| Galderma Laboratories, L.P. May 29, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to CLEARWATER, FL · in-kind | $30.00 |
| Amgen Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $650 |
| Galderma Laboratories, L.P. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Amgen Inc. May 8, 2025 | Travel and Lodging OTEZLA · Inflammation · travel to LAKELAND, FL · in-kind | $1,050 |
| Amgen Inc. Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $1,625 |
| Amgen Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $650 |
| Amgen Inc. Apr 15, 2025 | Travel and Lodging OTEZLA · Inflammation · travel to SARASOTA, FL | $199 |
| Amgen Inc. Apr 11, 2025 | Travel and Lodging OTEZLA · Inflammation · travel to SARASOTA, FL · in-kind | $281 |
| Galderma Laboratories, L.P. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Galderma Laboratories, L.P. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Amgen Inc. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $3,900 |
| Amgen Inc. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) OTEZLA · Inflammation | $650 |
| Amgen Inc. Mar 5, 2025 | Travel and Lodging OTEZLA · Inflammation · travel to CLERMONT, FL · in-kind | $932 |
| Galderma Laboratories, L.P. Feb 10, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $2,700 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 7 companies. The companies reported $782,110 in research payments for these studies, mostly to the institutions running them.
- TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic hand and foot d…
Eli Lilly and Company - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. · Active, not recruiting · NCT06468228 - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation - A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Incyte Corporation - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
Janssen Research & Development, LLC - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderat…
Janssen Research & Development, LLC - M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. - A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 52 weeks of treatment
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.